Actively Recruiting
Evaluation of EO2002 Injection for Corneal Edema Due to Endothelial Dysfunction Comparing Two Dose Levels and Placebo
Led by Emmecell · Updated on 2026-10-09
121
Participants Needed
10
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of EO2002, an investigational magnetic human corneal endothelial cell therapy, in adults with corneal edema caused by corneal endothelial dysfunction. The study compares two doses of EO2002 against a placebo injection to assess their impact on vision and corneal thickness. This Phase 2 trial is randomized and double-masked, involving about 105 participants at multiple sites in the United States. Participants will receive a single intracameral injection of EO2002 at either 150,000 or 500,000 magnetic human corneal endothelial cells, or a placebo injection with no cells. The study follows participants for 52 weeks, monitoring changes in best-corrected visual acuity and central corneal thickness to evaluate treatment effects and safety. During the study, participants will have regular assessments to monitor vision and corneal thickness, along with safety evaluations over the 52-week follow-up. Researchers will measure best-corrected visual acuity at 26 weeks as the primary outcome. Participants will be observed through scheduled visits to track treatment effects and any side effects throughout the trial duration.
CONDITIONS
Brief Title
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Research Team
C
Clinical Operations - Emmecell
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here